ArticleCureus2026
Outpatient Phenibut Taper Supported by Baclofen and Gabapentin.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phenibut (β-phenyl-γ-aminobutyric acid) is a non-regulated gamma-aminobutyric acid (GABA)ergic compound associated with dependence and a clinically significant withdrawal syndrome characterized by anxiety, insomnia, and autonomic symptoms. Evidence-based guidance for phenibut withdrawal management is limited. We describe a 27-year-old male with phenibut dependence who achieved cessation in an outpatient setting using a gradual phenibut taper supported by baclofen and adjunctive gabapentin. Phenibut was tapered from approximately 2.5 g/day to cessation over nine weeks. Baclofen and gabapentin were introduced as adjunctive agents during the taper and subsequently discontinued. The patient's scheduled left shoulder labral repair surgery served as a significant external motivator for cessation. This case illustrates the feasibility of a clinician-guided outpatient taper strategy incorporating pharmacologic support in a motivated patient, while highlighting important limitations related to attribution of treatment effects and follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.